| ALK

What is asthma

One airway, one disease

Allergic Asthma

Asthma and rhinitis are closely linked.
Last updated: 09.11.2016

What is allergy

Do you suffer from allergic disease?

What is allergy?

Respiratory allergic disease is often seen as a modern condition associated with increasing pollution, greater use of pesticides, environmental toxins and global warming. However, the key to defeating allergic disease lies in reprogramming our own immune system.

Key respiratory allergens

Read about house dust mites
Read about pollens
Last updated: 28.11.2016

Careers

Do you want to join ALK?

Careers

Become part of a team that is passionate about making a difference for everyone touched by allergy
The chance to learn
We offer on-the-job training and continuous development, making every day an opportunity for growth. To ensure this translates into long-term development, every employee is encouraged to have a clear career plan.
The opportunity to lead
ALK’s global leadership development programme focuses on strategy execution and leading change, with managers and employees working together to identify the skills necessary to achieve our future business targets.
A world of possibilities
Our employees work across borders and cultures, sharing expertise and promoting knowledge transfer across the company. We also actively encourage global job rotation across our departments and markets.
Last updated: 08.07.2019

Our company

About ALK

Allergy solutions for life

ALK is a global allergy solutions company, with a wide range of allergy treatments, products and services that meet the unique needs of allergy sufferers, their families and healthcare professionals.

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage. With 100 years of experience, nobody knows allergy like us, and we continuously apply our scientific knowledge and expertise to help people take control of their allergy and their life.

We want to make a difference by offering solutions for everyone who is touched by allergy – through a comprehensive range of products, services and resources that offer a fast-track to a more balanced life.

A century of helping severe allergy sufferers

ALK's heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, together with our global partners, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.
Last updated: 11.05.2021

Our solutions

Managing allergies

Solutions for the world's allergies

We want to make a difference by offering solutions for everyone who is touched by allergy – through a comprehensive range of products, services and resources that offer a fast-track to a more balanced life.

Our solutions

Consumer healthcare
We have expanded with a new consumer healthcare division that offers new products and services via a webshop to help people manage their allergies.
Diagnostics
The first step in being able to optimally treat any allergy is getting a definitive diagnosis. As well as treatments, ALK also makes allergen extracts for use in allergy diagnosis tools, such as skin prick tests.
Allergy vaccines
Allergy immunotherapy is a treatment for respiratory allergies that works by treating the underlying cause of the allergy. At ALK, we specialise in evidence-based products that rebalance the immune system by gradually building up tolerance to allergens.
Emergency treatment
For some people, exposure to specific food or a bee or wasp stings can trigger an acute allergic reaction also known as anaphylaxis. This can lead to respiratory arrest if quick and effective emergency treatment is not given.
Last updated: 05.07.2019

Patients

Do you suffer from allergic disease?

Patients

Worldwide industrialisation and lifestyle changes have had a major impact on the development of respiratory allergies. Allergy immunotherapy can help patients to take control of their allergies by reprogramming their immune system.

Addressing a global problem

Respiratory allergy - facts and figures
Globally, 400-500 million people are affected by allergic rhinitis, and 10-20% of these have symptoms which are not well controlled. People who experience insufficient effect from symptomatic medication can benefit from allergy immunotherapy.
The connection beween allergic rhinitis and allergic asthma
It is well established that respiratory allergies can lead to both allergic rhinitis and allergic asthma, which although often treated separately in the past, are increasingly being seen as different manifestations of a single condition.
Treating allergy
The most important difference between allergy immunotherapy treatment and treatments that only suppress allergy symptoms for a short time is that immunotherapy reprogrammes the body to induce immunological tolerance, thus altering the course of the disease.
Last updated: 09.07.2019

Front Page

ALK

Celebrating the past and future of allergy solutions for life

Front_page_1
Front_page_2

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy

News

  • Post date
    05/08/2025
    ITULATEK® approved for treatment of children and adolescents in Canada
  • Post date
    05/06/2025
    Three-month interim report (Q1) 2025 (unaudited)
  • Post date
    05/02/2025
    ALK enters into neffy® co-promotion agreement in the USA
  • Post date
    04/29/2025
    Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025
  • Post date
    04/23/2025
    ITULAZAX® tree pollen tablet approved for treatment of children in Europe
  • Post date
    04/03/2025
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
  • Post date
    03/13/2025
    Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
  • Post date
    03/07/2025
    ACARIZAX® approved in Canada for treatment of young children
  • Post date
    03/04/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
ALK Corporate Strategy 2024-2028
As the pioneers of allergy solutions, we are stepping into the next 100 years with a mission to help more people, with more solutions, more efficiently. We call it Allergy+.
100 Years of Pioneering Allergy Solutions
A new book has been written about ALK’s fascinating development in the field of allergy
The hunt for a vaccine – a podcast in five episodes
A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.
Last updated: 04.06.2024